Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins

White matter ischemia is difficult to quantify histologically. Myelin-associated glycoprotein (MAG) is highly susceptible to ischemia, being expressed only adaxonally, far from the oligodendrocyte cell body. Myelin-basic protein (MBP) and proteolipid protein (PLP) are expressed throughout the myelin...

Full description

Bibliographic Details
Main Authors: Barker, R, Wellington, D, Esiri, M, Love, S
Format: Journal article
Language:English
Published: 2013
_version_ 1797050602853761024
author Barker, R
Wellington, D
Esiri, M
Love, S
author_facet Barker, R
Wellington, D
Esiri, M
Love, S
author_sort Barker, R
collection OXFORD
description White matter ischemia is difficult to quantify histologically. Myelin-associated glycoprotein (MAG) is highly susceptible to ischemia, being expressed only adaxonally, far from the oligodendrocyte cell body. Myelin-basic protein (MBP) and proteolipid protein (PLP) are expressed throughout the myelin sheath. We compared MAG, MBP, and PLP levels in parietal white matter homogenates from 17 vascular dementia (VaD), 49 Alzheimer's disease (AD), and 33 control brains, after assessing the post-mortem stability of these proteins. Small vessel disease (SVD) and cerebral amyloid angiopathy (CAA) severity had been assessed in paraffin sections. The concentration of MAG remained stable post-mortem, declined with increasing SVD, and was significantly lower in VaD than controls. The concentration of MBP fell progressively post-mortem, limiting its diagnostic utility in this context. Proteolipid protein was stable post-mortem and increased significantly with SVD severity. The MAG/PLP ratio declined significantly with SVD and CAA severity. The MAG and PLP levels and MAG/PLP did not differ significantly between AD and control brains. We validated the utility of MAG and MAG/PLP measurements on analysis of 74 frontal white matter samples from an Oxford cohort in which SVD had previously been scored. MAG concentration and the MAG/PLP ratio are useful post-mortem measures of ante-mortem white matter ischemia. © 2013 ISCBFM.
first_indexed 2024-03-06T18:07:36Z
format Journal article
id oxford-uuid:01f4b703-343b-46d3-8b41-7488727133ad
institution University of Oxford
language English
last_indexed 2024-03-06T18:07:36Z
publishDate 2013
record_format dspace
spelling oxford-uuid:01f4b703-343b-46d3-8b41-7488727133ad2022-03-26T08:37:53ZAssessing white matter ischemic damage in dementia patients by measurement of myelin proteinsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:01f4b703-343b-46d3-8b41-7488727133adEnglishSymplectic Elements at Oxford2013Barker, RWellington, DEsiri, MLove, SWhite matter ischemia is difficult to quantify histologically. Myelin-associated glycoprotein (MAG) is highly susceptible to ischemia, being expressed only adaxonally, far from the oligodendrocyte cell body. Myelin-basic protein (MBP) and proteolipid protein (PLP) are expressed throughout the myelin sheath. We compared MAG, MBP, and PLP levels in parietal white matter homogenates from 17 vascular dementia (VaD), 49 Alzheimer's disease (AD), and 33 control brains, after assessing the post-mortem stability of these proteins. Small vessel disease (SVD) and cerebral amyloid angiopathy (CAA) severity had been assessed in paraffin sections. The concentration of MAG remained stable post-mortem, declined with increasing SVD, and was significantly lower in VaD than controls. The concentration of MBP fell progressively post-mortem, limiting its diagnostic utility in this context. Proteolipid protein was stable post-mortem and increased significantly with SVD severity. The MAG/PLP ratio declined significantly with SVD and CAA severity. The MAG and PLP levels and MAG/PLP did not differ significantly between AD and control brains. We validated the utility of MAG and MAG/PLP measurements on analysis of 74 frontal white matter samples from an Oxford cohort in which SVD had previously been scored. MAG concentration and the MAG/PLP ratio are useful post-mortem measures of ante-mortem white matter ischemia. © 2013 ISCBFM.
spellingShingle Barker, R
Wellington, D
Esiri, M
Love, S
Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins
title Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins
title_full Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins
title_fullStr Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins
title_full_unstemmed Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins
title_short Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins
title_sort assessing white matter ischemic damage in dementia patients by measurement of myelin proteins
work_keys_str_mv AT barkerr assessingwhitematterischemicdamageindementiapatientsbymeasurementofmyelinproteins
AT wellingtond assessingwhitematterischemicdamageindementiapatientsbymeasurementofmyelinproteins
AT esirim assessingwhitematterischemicdamageindementiapatientsbymeasurementofmyelinproteins
AT loves assessingwhitematterischemicdamageindementiapatientsbymeasurementofmyelinproteins